好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Platelet Rich Plasma in the Management of Vertebrogenic and Discogenic Pain
Pain
P5 - Poster Session 5 (5:30 PM-6:30 PM)
13-004
To elucidate the role of platelet-rich plasma in treating vertebrogenic and discogenic pain.
Lower back pain is a commonly encountered problem in the United States that can be attributed to a multitude of factors. Pathologies such as intervertebral disk(IVD) degeneration leading to discogenic pain, vertebral end plate damage leading to chronic vertebrogenic pain are two common causes of back pain. Platelet-rich plasma(PRP) is an emerging medical treatment that is high in autologous platelets, growth factors, cytokines, and chemokines.
The inclusion criterias were randomized controlled trials and observational studies that used PRP as therapy for vertebrogenic/discogenic back pain. The exclusion criterias included case reports, case series, animal studies, letters, editorials, conference abstracts, and other studies not related to vertebrogenic or discogenic pain. The outcome measured was ODI score and the impact of PRP therapy on their quality of life.

The use of PRP in vertebrogenic and discogenic pain has been the subject of several studies. In a preliminary clinical trial, Akeda et al.found  out that intradiscal injection of autologous PRP releasate was safe and had started show efficacy in patients with discogenic low back pain.Similar results were found in the studies by Lutz et al. with higher-concentration PRP injections in patients with chronic discogenic pain. We encountered several limitations, including a relatively small sample size, a brief follow-up period, patient heterogeneity, and limited generalizability. Therefore, more studies should be conducted for the implementation of PRP for the management of low back pain. 
The available meta-analyses and systematic reviews indicate that individuals treated with PRP for chronic discogenic back pain had significant improvement in pain and function. However, the modest sample size of studies may curtail the ability to generalize findings effectively and attain statistical power. Further research is needed to be able to generalize PRP therapy to a broader patient population.
Authors/Disclosures
Omar Elsekaily, MBBS (LSU shreveport)
PRESENTER 		Dr. Elsekaily has nothing to disclose.
Saurabh Kataria, MD (Pier Landing) Dr. Kataria has nothing to disclose.
Utsav Patel Utsav Patel has nothing to disclose.
Jeremiah H. Wijaya No disclosure on file
Kevin Yabut Kevin Yabut has nothing to disclose.
Muhammad Ayub, MD (Louisiana State University, Shreveport) Dr. Ayub has nothing to disclose.
Muhammad Khalid, MD (LSU shreveport) Dr. Khalid has nothing to disclose.
Tooba Aslam No disclosure on file
Alan Kaye (LSUHSC Sghreveport) Alan Kaye has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Heliyon Journal. Alan Kaye has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Physician Journal. Alan Kaye has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports.